GLOBAL DEAL SYNDICATION
HBS Alumni Angels syndicates selected deals across the full global membership of its 14 chapters. This enables selected deals from one chapter to reach a global network of accredited investor alumni. This is a unique benefit of being a member in a local HBS Alumni Angel chapter. Investment decisions are made and executed individually following a global webinar. Once investments are made, investors often assist companies in other areas as formal or informal advisers. For details on how the process works, please scroll down.
UPCOMING SYNDICATION CALLS
SAVE THE DATE
GLOBAL SYNDICATED INVESTMENT PRESENTATION:
SUNRAY SCIENTIFIC
Sunray Scientific offers custom-engineered interconnect solutions for advanced electronic packaging.
Thursday, November 7, 2024 9am PT, 12pm ET, 5pm London, 6pm Continental Europe
Presenter: Madhu Stemmermann, CEO of Sunray Scientific
​
For HBS Angels Members ONLY
On behalf of the New York chapter, we would like to share the following investment opportunity:
MORE INFORMATION COMING SOON!
LUPII
SUNRAY SCIENTIFIC
CO-FOUNDER & CEO
Madhu Stemmermann Sunray Scientific Co-Founder, and CEO
-
25+ years of experience in senior leadership roles across sales, manufacturing, supply chain, engineering and product management
-
Focus areas include: environmental health & safety, customer focus, quality, lean six sigma
-
She has worked across various industries such as medical devices, lighting and electronics with Becton Dickinson, Air Products, Honeywell and General Electric
The Zoom Meeting information will be in your registration confirmation email.
SAVE THE DATE
GLOBAL SYNDICATED INVESTMENT PRESENTATION:
VON VASCULAR
Vonvascular.io is a disruptive MedTech company with a focused mission: to transform lives through disruptive technology that makes thrombectomy better.
Thursday, November 21, 2024 9am PT, 12pm ET, 5pm London, 6pm Continental Europe
Presenter: Manning Hanser, CEO of Von Vascular
​
For HBS Angels Members ONLY
On behalf of the Charlotte chapter, we would like to share the following investment opportunity:
MORE INFORMATION COMING SOON!
LUPII
Von Vascular
CO-FOUNDER & CEO
Manning Hanser, CEO, Eighteen years of leadership & Commercial development in the medical device industry. A dynamic, results-driven professional who leads with integrity and a rigid work ethic. Extensive expertise in sales, business development initiatives, marketing, technology evaluations, fundraising, and strategic operations. Proven capacity to strategically design and execute sales and marketing strategies that produce value, portfolio expansion, brand equity, market share, ROI, and operational efficiencies. Self-directed and driven by integrity. Proven success in business development, program management, and product expansion through strong industry relationships, global physician relationships, strategic partnerships, internal collaboration, operational expertise, and a consultative approach that consistently addresses strategic objectives, meets milestones and stays within budget. Successful track record in a highly competitive, high-pressure sales and product development environment.
The Zoom Meeting information will be in your registration confirmation email.
PREVIOUS SYNDICATION CALL
GLOBAL SYNDICATED INVESTMENT PRESENTATION:
Pathotrak
Foodborn Pathogen Detection Kits
USDA & FDA compliant with the fastest Time to Results on the market
Thursday, September 19, 2024 9am PT, 12pm ET, 5pm London, 6pm Continental Europe
Presenter: Javier Atencia, PhD, Founder & CEO of Pathotrak
​
For HBS Angels Members ONLY
MILESTONES
On behalf of the Washington DC chapter, we would like to share the following investment opportunity:
Pathotrak’s technology reduces the detection time of food-safety tests from 1-2 days to as little as 2.5 hours, helping food manufacturers cut costs on staffing, warehousing, and refrigeration, enabling earlier product release and faster recalls, and avoiding outbreaks.
From August 2015 to January 2016, Chipotle hemorrhaged $8 billion in market value following an E. coli outbreak. This incident was merely one of roughly 1,000 such cases that transpire yearly in the United States, leading to aggregate financial losses surpassing $55 billion, coupled with illness and mortality. The prevailing 1-2 day "rapid" testing methods compel the food industry to strike a balance between product shelf-life and profitability versus consumer safety, and creates a bottleneck in the food supply chain that persists to this day.
PROBLEM & MARKET
The government is tightening food safety testing regulations. PCR, the gold standard for detecting pathogens, requires 22 to 48 hours for "enrichment" to grow pathogens to detectable levels, with no viable alternative currently available. In the US, the Total Addressable Market (TAM) for pathogen testing is $19 billion. The Serviceable Addressable Market (SAM), focusing on Salmonella, E. coli, and Listeria testing, is valued at $7.9 billion, 66.4% of the TAM. Our initial Target Markets, Meat and Produce, represent a combined $1.7 billion market value.
SOLUTION
Pathotrak’s AOAC-accredited, award-winning technology separates pathogens directly from the food sample after as little as 3.5 hours of incubation for beef, 5.5 hours for fresh produce, and no time at all for poultry. Our technology enables in-line product food-safety testing and the release of product within a single 8-hour shift. It is the first and only AOAC accredited technology to be this fast and as accurate as the 3-4 days FDA standard method for testing.
GO TO MARKET STRATEGY
Current customer-segment: (2 customers, 8 prospective in pipeline) Top-ten contract labs, covering over 50% of the contract testing market, growing at 9% CAGR. Our disposables offer competitive advantage on turnaround time and increased capacity.
Second customer-segment: Corporate (high-throughput) labs of large food producers. Our disposables cut logistic costs and increase shelf life.
COMPETITION
Our product is complementary to most commercial detection technologies and we directly compete with vendors of enrichment media and enrichment disposables – Neogen, Bio-Rad, BioMerieux, ThermoFisher, Hygiena etc. These competitors have expressed interest in Pathotrak as a ‘game changer’, and we have partnered with four of them for common regulatory approval.
FINANCIAL INFORMATION
Capital raised:
Non-dilutive $1.5M
Preseed $3.5M
Seed $1.5M
Total funding $6.5M
Stage: Pre-Series A Bridge
TEAM
-
CEO & Founder: Javier Atencia, Tech Inventor. 15 years experience at NIST and UMD. 9 patents, 4 licensed.
-
CFO: Rick Faint, experienced lawyer and entrepreneur. 2 IPOs, 6 Exits.
-
Chief Commercial Officer: Colin Howell, 25-year international business leader and entrepreneur.
-
Engineering: Ethan Reggia, Carson Myers, Nitay Ravin, Andy Gregory.
-
Microbiology: Alexa Grace Baldwin, Jennifer Kuhlman.
-
Business Development: Sean Martinos.
ADVISORY BOARD
-
Food safety: Dr. Robert Buchanan; 30 years at FDA, USDA & UMD.
-
Product development: Joan Savall, Ph.D. Director of Robotics @ Johnson & Johnson.
-
Business: Deborah Hemingway, Ph.D., serial entrepreneur.
-
Business: Doug Humphrey, VC-backed serial entrepreneur, 2 IPO.
LUPII
Pathotrak
CO-FOUNDER & CEO
Javier Atencia, PhD, Pathotrak Founder, and CEO, has over ten years of project leader experience at UMD/NIST in microbiology and microfluidics. He has published his research work in Nature and other journals. He is the inventor of Pathotrak’s award-winning technology and holds 8 patents (three licensed; one to Intel). Javier leads strategy, creative design, implementation, and operations for Pathotrak. He brings to the team a multidisciplinary background leading cross-disciplinary teams and working with large strategic partners for cutting-edge solutions.
PAST SYNDICATED COMPANIES
HOW IT WORKS
Use arrows on the side to navigate
CRITERIA
Ideally, for global syndication a company should meet the following requirements:
-
Local host chapter members committed to invest at least $50,000* and local chapter forwards deal to global for syndication;
-
Company assures at least $50,000-100,000 investible capacity;
-
Company provides at least 2 weeks for due diligence following the webinar, prior to requiring an investment decision;
-
Minimum individual investment amount is set at $25,000 or less;
-
Company agrees to a one-time admin fee of $1500.
The Global Syndication Committee selects the most suitable company candidates from the 15 participating HBSAA chapters and is aiming to host monthly webinars.
​
*NY and other larger chapters may have a $100,000 min.